IRBM Expands Global Reach in Drug Discovery with New Boston Office

March 05, 2024 11:24 PM AEDT | By Cision

Google News:

IRBM Expands Global Reach in Drug Discovery with New Boston Office — Image source: Kalkine Media

Recent News

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Storie...

Cisco: Crisis Response Community Volunteers Know What It Takes To Stay...

ACCP Releases 2025 Making the Case Toolkit Communicating the Business...

Could Mayne Pharma’s Takeover Evaluation Shift Sentiment on ASX Health...

Strategic Growth and Increased Visibility Set to Enhance IRBM's Leadership Position

ROME, March 5, 2024 /PRNewswire/ -- IRBM, an integrated drug discovery Contract Research Organization (CRO), announces its global expansion with a new office in Boston, Massachusetts, a cornerstone for biotechnology and drug discovery. This strategic initiative underscores IRBM's dedication to fostering innovation and collaboration within the life sciences sector, aiming to harness Boston's dynamic biotech ecosystem for the accelerated development of therapies that address unmet medical needs on a larger scale.

Expanding IRBM's global reach, the Boston site will enhance direct interactions with partners, collaborators, and the broader scientific community across the United States and internationally. This move reinforces IRBM's mission to improve health outcomes through innovative research and an integrated, collaborative approach to drug discovery.

Matteo Liguori, CEO of IRBM, expressed his enthusiasm about the expansion: "Opening our first international office in Boston marks a significant milestone in IRBM's journey, reflecting our commitment to advancing science and health on a global scale. We are excited to be part of Boston's vibrant biotech ecosystem, which will support us in facilitating new collaborations and accelerating our contributions to drug discovery and the scientific community."

In tandem with the opening of the Boston office, IRBM is pleased to announce the launch of its redesigned website (https://www.irbm.com/), which offers a more intuitive and user-friendly experience. The website provides detailed insights into IRBM's research, capabilities, and partnership opportunities, reflecting the company's efforts to improve engagement with the global scientific community, partners, and the public.

The introduction of IRBM's Boston office and the launch of its redesigned website signify major strides in the company's global outreach and digital engagement. IRBM welcomes current and future collaborators and partners to arrange a visit to the new Boston location and to explore the updated website, actions that underscore IRBM's commitment to advancing health through scientific innovation and partnership.

About IRBM

IRBM is a global leader in drug discovery, boasting a unique model of conducting all research at a single site, fostering unparalleled agility and efficiency from concept to candidate. This model facilitates rapid breakthroughs while minimizing setbacks. With a history of contributing to four approved drugs, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. IRBM's comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning them as a major player in driving innovation across the pharmaceutical and biotech industry.Top of Form

Website: https://www.irbm.com/

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.